NCT05498727 is a clinical trial of Integration of SARS-CoV 2 Testing in HIV, MNCH and TB Clinics in COVID-19, sponsored by Elizabeth Glaser Pediatric AIDS Foundation.

Who is sponsoring NCT05498727?

NCT05498727 is sponsored by Elizabeth Glaser Pediatric AIDS Foundation.

What drugs are being tested in NCT05498727?

Interventions in NCT05498727: Integration of SARS-CoV 2 Testing in HIV, MNCH and TB Clinics.

Is NCT05498727 still recruiting?

NCT05498727 is currently completed. Last updated 11 January 2024.

Last reviewed 2024-01-11 · How we verify

NCT05498727

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of the Integration of Ag-RDTs for COVID-19 in MNCH, HIV and TB Services in Cameroon and Kenya

Completed Last updated 11 January 2024

What this trial tests

trial testing Integration of SARS-CoV 2 Testing in HIV, MNCH and TB Clinics in COVID-19 in 527,184 participants. Completed in 30 September 2023.

Timeline

2 May 2022

Primary endpoint
31 October 2022

30 September 2023

Quick facts

Lead sponsor	Elizabeth Glaser Pediatric AIDS Foundation
Status	Completed
Study type	OBSERVATIONAL
Enrollment	527,184
Start date	2 May 2022
Primary completion	31 October 2022
Estimated completion	30 September 2023
Sites	2 locations across Kenya, Cameroon

Drugs / interventions tested

Integration of SARS-CoV 2 Testing in HIV, MNCH and TB Clinics

Conditions studied

COVID-19 — all drugs for COVID-19 →

Sponsor

Elizabeth Glaser Pediatric AIDS Foundation

Who can join

2 and older, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In many national Coronavirus Disease 2019 (COVID-19) response plans, including in Kenya and Cameroon, antigen detection tests are being used to improve access for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) testing. Targeting the populations most at risk for COVID-19 disease, including pregnant women, people living with HIV, and patients with tuberculosis (TB), and those who are the most vulnerable to transmission to other populations, can reduce the negative impact of the SARS-CoV-2 pandemic. Catalyzing COVID-19 Action (CCA) aims to strengthen detection by screening and diagnosing cases of SARS-CoV-2 in MNCH clinics, HIV clinics, and TB clinics and enhancing the management of COVID-positive cases. The main goal of the CCA project is to reduce deaths and severe illnesses caused by COVID-19 through early access to reliable diagnosis and effective treatment through innovative models of care. Both countries will conduct a pre- and post-implementation evaluation to compare screening, testing, care, and treatment of patients undergoing COVID-19 screening, testing, and treatment before and after the integration of facilities taking part in the CCA project.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Integrating SARS-CoV-2 rapid antigen testing in maternal, neonatal and child health, HIV, and TB clinics in Kenya and Cameroon: outcomes from the Catalysing COVID-19 Action Project.
Tchounga BK, Hoffman N, Masaba R, Djikeussi T, et al · · 2024 · PMID 41221322 · DOI 10.1136/bmjph-2024-001015

Verify or expand the search:

Other recruiting trials for COVID-19

Currently open trials in the same condition.

NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting

Other Elizabeth Glaser Pediatric AIDS Foundation trials

Trials by the same sponsor.

NCT05684887 — Digital Tools to Expand COVID-19 Testing in Exposed Individuals in Cameroon · NA · completed
NCT05529771 — Clinical Outcomes of paTients pREsenting to HArare COVID-19 CenTer of Excellence With SARS-CoV-2 Infection · completed
NCT05458557 — Antigen Rapid Diagnostic Tests for Community Identification of Severe Acute Respiratory Syndrome Coronavirus 2 · completed
NCT05382130 — INTEGrating Ag-RDTs for COVID-19 in MNCH,HIV and TB Services in Cameroon and Kenya · NA · completed
NCT05341791 — Paper Versus Cartoon Video-based Administration of Study Information Notice for Participant Consent · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05498727 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Elizabeth Glaser Pediatric AIDS Foundation
Last refreshed: 11 January 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05498727.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing